Teva, AbCellera Sign Pact for Rare mAbsBy
Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies.
Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
AbCellera is a privately held company that has developed a high-throughput platform for the discovery of therapeutic antibodies directly from natural immune cells. The company's proprietary single cell technology can be applied across multiple species and provides f assay formats to identify antibodies with defined properties at a throughput of millions of B cells per run.
Source: Teva Pharmaceutical Industries